These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 28455584

  • 1. Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
    Nishijima-Futami Y, Minami S, Futami S, Koba T, Higashiguchi M, Tamiya M, Suzuki H, Hirashima T, Komuta K, Kijima T.
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1215-1220. PubMed ID: 28455584
    [Abstract] [Full Text] [Related]

  • 2. A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
    Yamada K, Ichiki M, Takahashi K, Hisamatsu Y, Takeoka H, Azuma K, Shukuya T, Nishikawa K, Tokito T, Ishii H, Hoshino T.
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):501-7. PubMed ID: 27402398
    [Abstract] [Full Text] [Related]

  • 3. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
    Nishino K, Imamura F, Kumagai T, Katakami N, Hata A, Okuda C, Urata Y, Hattori Y, Tachihara M, Yokota S, Nishimura T, Kaneda T, Satouchi M, Morita S, Negoro S.
    Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
    Tamiya A, Tamiya M, Shiroyama T, Saijo N, Nakatani T, Minomo S, Tsuji T, Takeuchi N, Omachi N, Kurata K, Suzuki H, Okamoto N, Okishio K, Hirashima T, Atagi S.
    Med Oncol; 2015 Mar; 32(3):40. PubMed ID: 25616723
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
    Miyanaga A, Kubota K, Hosomi Y, Okuma Y, Minato K, Fujimoto S, Okamoto H, Satouchi M, Isobe H, Aono H, Takiguchi Y, Gemma A, Tokyo Cooperative Oncology Group.
    Jpn J Clin Oncol; 2019 Aug 01; 49(8):749-754. PubMed ID: 31070750
    [Abstract] [Full Text] [Related]

  • 6. Switch maintenance chemotherapy using S-1 with or without bevacizumab in patients with advanced non-small cell lung cancer: a phase II study.
    Niho S, Ohe Y, Ohmatsu H, Umemura S, Matsumoto S, Yoh K, Goto K.
    Lung Cancer; 2017 Jun 01; 108():66-71. PubMed ID: 28625650
    [Abstract] [Full Text] [Related]

  • 7. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
    Kuyama S, Ochi N, Bessho A, Hotta K, Ikeda G, Kishino D, Kubo T, Harada D, Fujimoto N, Nakanishi M, Umeno T, Okada T, Chikamori K, Yamagishi T, Ohashi K, Ichihara E, Takigawa N, Tanimoto M, Kiura K.
    Lung Cancer; 2017 Oct 01; 112():188-194. PubMed ID: 29191594
    [Abstract] [Full Text] [Related]

  • 8. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
    Urata Y, Okamoto I, Takeda M, Hattori Y, Okuno K, Shimada T, Kurata T, Kaneda H, Miyazaki M, Terashima M, Tanaka K, Morita S, Nakagawa K, Negoro S, Satouchi M.
    Cancer; 2013 Jun 15; 119(12):2275-81. PubMed ID: 23558513
    [Abstract] [Full Text] [Related]

  • 9. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y, Satouchi M, Shimada T, Urata Y, Yoneda T, Mori M, Nishimura T, Sunadome H, Kumagai T, Imamura F, Fujita S, Kaji R, Hata A, Tachihara M, Morita S, Negoro S.
    Lung Cancer; 2015 Feb 15; 87(2):136-40. PubMed ID: 25553650
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T, Tsai CM, Tsao CJ, Milanowski J, Amoroso D, Heo DS, Groen HJ, Szczesna A, Chung CY, Chao TY, Middleton G, Zeaiter A, Klingelschmitt G, Klughammer B, Thatcher N.
    Lung Cancer; 2013 Nov 15; 82(2):276-81. PubMed ID: 23992877
    [Abstract] [Full Text] [Related]

  • 11. Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
    Yang L, Yang S, Liu Y, Li J, Hu X, Wang Y, Zhang Y, Wang Y.
    Thorac Cancer; 2018 Jun 15; 9(6):693-698. PubMed ID: 29655198
    [Abstract] [Full Text] [Related]

  • 12. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, Nagase S, Okamoto I, Yamanaka T, Tajima K, Harada R, Fukuoka M, Yamamoto N.
    Lancet Oncol; 2014 Oct 15; 15(11):1236-44. PubMed ID: 25175099
    [Abstract] [Full Text] [Related]

  • 13. Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
    Chihara Y, Yoshimura A, Date K, Takemura Y, Tamiya N, Kohno Y, Imabayashi T, Takeuchi M, Kaneko Y, Yamada T, Ueda M, Arimoto T, Uchino J, Iwasaki Y, Takayama K.
    Oncologist; 2019 Aug 15; 24(8):1033-e617. PubMed ID: 31040252
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer.
    Kaira K, Tomizawa Y, Yoshino R, Miura Y, Yoshii A, Iwasaki Y, Koga Y, Ono A, Hisada T, Minato K, Sato K, Kazama T, Ishihara S, Kohyama K, Fueki N, Saito R, Sunaga N.
    Lung Cancer; 2013 Oct 15; 82(1):103-8. PubMed ID: 23927884
    [Abstract] [Full Text] [Related]

  • 15. A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102.
    Yokoi T, Minami S, Shiroyama T, Koba T, Torii Y, Sugimoto H, Niki M, Mori M, Morimura O, Hirashima T, Komuta K, Kijima T.
    Intern Med; 2019 May 15; 58(10):1405-1410. PubMed ID: 30713297
    [Abstract] [Full Text] [Related]

  • 16. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial.
    Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H.
    Clin Cancer Res; 2004 Dec 01; 10(23):7860-4. PubMed ID: 15585618
    [Abstract] [Full Text] [Related]

  • 17. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
    Kaira K, Imai H, Souma R, Sakurai R, Miura Y, Sunaga N, Kasahara N, Tsukagoshi Y, Koga Y, Kitahara S, Kotake M, Minato K, Naruse I, Fukushima Y, Hisada T, Ishizuka T.
    Anticancer Res; 2019 May 01; 39(5):2483-2491. PubMed ID: 31092443
    [Abstract] [Full Text] [Related]

  • 18. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct 01; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

  • 19. Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer.
    Goya H, Kuraishi H, Koyama S, Ichiyama T, Yoshiike F, Hirai K, Agatsuma T, Tateishi K, Kanda S, Yamamoto H, Kubo K, Koizumi T.
    Cancer Chemother Pharmacol; 2012 Nov 01; 70(5):691-7. PubMed ID: 22941346
    [Abstract] [Full Text] [Related]

  • 20. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH.
    Cancer Chemother Pharmacol; 2013 Nov 01; 72(5):1103-10. PubMed ID: 24057043
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.